For The Better

Which battered growth stock has a better shot at a recovery?

This burgeoning footwear business grew revenue more than 50% in its latest quarter.

These Buffett-backed stocks look like long-term winners.

Should you steer clear of this pharma giant?

These fast-growing companies don’t pay a dividend yet, but could one day.

GrafTech’s stock has been decimated this year based on macroeconomic concerns, creating an opportunity to buy the dip.

There’s always risk in investing, but it’s tough to ignore the rewards.

These stocks offer above-average return potential for long-term investors.

Shares could be far too cheap to ignore for the right investor.

The bank has struggled since its phony-accounts scandal, but has also started to turn things around over the last few years.

The top cryptocurrency still deserves investors’ attention.

If investors don’t want to buy shares, then management will.

These lower-risk stocks have enormous upside potential.

Could this high-growth cloud stock become a cloud king?

These consumer stocks continue to impress despite uncertain times.

Pfizer could be gearing up for a big acquisition.

The bloodbath may last a bit longer for these companies, but their prospects look attractive.

This isn’t a calculation you want to get wrong.

Alternatives to expensive cable packages are doing more — and faster — damage than once thought possible.

Making too much of these states’ stance toward benefits could mislead you.